DUBLIN, Jan. 2, 2025
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that
its Chief Executive Officer, Richard
Pops, will provide a corporate overview and update at the
43rd Annual J.P. Morgan Healthcare Conference. The
presentation will take place on Wednesday,
Jan. 15, 2025 at 11:15 a.m.
PST (2:15 p.m.
EST/7:15 p.m. GMT), followed
by a question and answer session. The live webcast may be accessed
under the Investors tab on www.alkermes.com and will be archived
for 14 days.
About Alkermes plc
Alkermes plc is a global
biopharmaceutical company that seeks to develop innovative
medicines in the field of neuroscience. The company has a portfolio
of proprietary commercial products for the treatment of alcohol
dependence, opioid dependence, schizophrenia and
bipolar I disorder, and a pipeline of clinical and preclinical
candidates in development for neurological disorders, including
narcolepsy and idiopathic hypersomnia. Headquartered
in Ireland, Alkermes
also has a corporate office and research and development
center in Massachusetts and a
manufacturing facility in Ohio.
For more information, please visit Alkermes' website
at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341496.html
SOURCE Alkermes plc
